After Promising Early Data on Gene Editing, Intellia Will Launch ATTR Trial This Year
A single dose of NTLA-2001, Intellia Therapeutics’ investigational gene editing therapy for transthyretin amyloidosis (ATTR), results in a sustained reduction in the levels of the damaging transthyretin (TTR) protein for at least one year, according to preclinical data. Based on these promising data in non-human primates,…